IFET has ensured full and uninterrupted patient access to trimethoprim/sulfamethoxazole antibiotics.

Following recent inaccurate public reports regarding a shortage of the antibiotic combination trimethoprim/sulfamethoxazole, IFET S.A. clarifies the following:

• Available stock is sufficient for a period exceeding three months.
• Following instructions from the National Organization for Medicines (EOF), IFET continues uninterruptedly the importation and distribution of both the injectable and oral forms of the product.
• Hospitals and pharmaceutical warehouses are supplied with the required quantities through a normal supply flow.
• Since 2013, IFET S.A. has consistently ensured the coverage of therapeutic needs through the provision of the product in oral suspension form.

IFET S.A., in close cooperation with EOF, systematically monitors the needs of the healthcare system and intervenes where necessary, prioritizing uninterrupted patient access to essential therapies.